At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see how well volrustomig works to treat people with inoperable head and neck squamous cell cancer (HNSCC). Inoperable means the cancer cannot be taken out with surgery. The people in this study have HNSCC that has not grown after chemotherapy and radiation given at the same time.
-
The usual care for people with squamous cell skin cancer is surgery, with or without radiation therapy. Sometimes the cancer comes back (recurs). For this reason, researchers are studying other treatments for squamous cell skin cancer.
-
When some cancers become advanced, particularly colorectal cancer, they may spread to the liver. Destroying the tissue with electromagnetic waves that produce extremely high temperatures, a procedure called "thermal ablation," is one way to treat these liver metastases.
- A Phase II Study of Trastuzumab Deruxtecan in People with HER2-Positive Solid Tumors
Full Title A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)
Purpose
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
Trastuzumab deruxtecan is an antibody drug conjugate (ADC). ADCs have two parts: the antibody targets cancer cells and the other part (a chemotherapy drug attached to the antibody) kills cancer cells. Trastuzumab, the antibody part, binds to HER2 on cancer cells. Deruxtecan is the cell-killing part. When trastuzumab sticks to HER2, deruxtecan is released and kills the cancer cell from within.
Trastuzumab deruxtecan is approved to treat metastatic breast cancer; its use in this study is investigational. It is given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable or metastatic HER2-positive biliary tract, bladder, cervical, endometrial, ovarian, or pancreatic cancer or a rare tumor.
- At least 4 weeks must pass since completion of prior therapy and receipt of trastuzumab deruxtecan.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Vicky Makker at 646-888-4224.
Protocol
21-078Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04482309ClinicalTrials.gov
-
The purpose of this study is to see how treatment for retinoblastoma in one eye affects quality of life in survivors of this cancer who had chemotherapy (injected into the eye) or surgery to remove the eye. Researchers will ask participants about their physical and emotional health and ability to perform daily activities. They want to determine if there are any differences between these treatments with respect to their effect on quality of life. It is hoped that this information will help doctors provide better care for children with retinoblastoma in the future and better follow-up care for survivors of this cancer.
-
This study is comparing the effectiveness of combination chemotherapy plus tucatinib and trastuzumab versus combination chemotherapy alone in people with metastatic colorectal cancer that is positive for the HER2 protein. The combination chemotherapy is called mFOLFOX6 (oxaliplatin, leucovorin or levoleucovorin, and fluorouracil) and it is a standard treatment for advanced colorectal cancer.
-
In this study, researchers are comparing ado-trastuzumab emtansine with the usual treatment (docetaxel and trastuzumab) in people with recurrent, inoperable, or metastatic salivary gland cancer that makes the HER2 protein. Ado-trastuzumab emtansine is a monoclonal antibody (trastuzumab) linked to a chemotherapy drug (emtansine). Trastuzumab attaches to HER2 on cancer cells and delivers emtansine to kill them.
-
Researchers are comparing two different treatments for breast cancer that metastasized (spread) and makes high levels of the HER2 protein. The people in this study have metastatic HER2-positive breast cancer that keeps growing after trastuzumab deruxtecan (T-DXd). Or they may have had bad side effects from this drug and had to stop taking it.
-
The purpose of this study is to compare proton beam radiation therapy with intensity-modulated radiation therapy (IMRT) in patients with stage I-IVA esophageal cancer. Both approaches send radiation inside the body to a tumor without damaging much of the healthy tissue around it. However, proton beam radiation therapy uses protons while IMRT uses photons (high-energy x-rays).
-
Peritoneal mesothelioma is a cancer of the inner lining of the abdomen (belly). The people in this study will be having surgery to take out as much of the cancer as possible. They will also receive heated chemotherapy given directly into the abdomen to kill any remaining cancer cells.